Hyperion Defi (HYPD) Intangibles (2023 - 2026)

Hyperion Defi (HYPD) posted quarterly Intangibles of $16.0 million for Q1 2026, down 22.13% quarter-over-quarter from $20.6 million in Q4 2025.

Hyperion Defi (HYPD) Intangibles (2023 - 2026) Analysis & Trends

Hyperion Defi (HYPD) has reported Intangibles for 4 consecutive years, with $16.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Intangibles changed N/A year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (changed N/A YoY), while the FY2025 annual figure was $20.6 million, changed N/A from the prior year.
Intangibles eased to $16.0 million in Q1 2026 per HYPD's latest filing, from $20.6 million in the prior quarter.
Across five years, Intangibles topped out at $35.0 million in Q3 2025 and bottomed at $2.1 million in Q3 2023.
Historically, Intangibles has averaged $11.8 million across 4 years, with a median of $6.1 million in 2024.
Annual changes were most pronounced in 2024 — Intangibles soared 188.42% — and 2025, when it soared 471.95%.
Hyperion Defi's Intangibles stood at $2.1 million in 2023, then jumped by 188.42% to $6.1 million in 2024, then surged by 236.3% to $20.6 million in 2025, then slipped by 22.13% to $16.0 million in 2026.
Business Quant data shows HYPD's Intangibles at $16.0 million in Q1 2026, $20.6 million in Q4 2025, and $35.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	140.00 Bn	132.14 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	86.31 Bn	78.32 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	65.24 Bn	60.06 Bn	1.37 Bn	266.00 Mn
4	Moderna	62.41 Bn	57.27 Bn	52.00 Mn	-
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	31.18 Bn	27.88 Bn	992.69 Mn	-
7	BioNTech SE	28.93 Bn	10.54 Bn	668.28 Mn	-
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	93.49 Mn
9	Royalty Pharma	27.28 Bn	26.44 Bn	-	-
10	Hyperion Defi	47.34 Mn	37.70 Mn	357,693.00	99.84 Mn

Download Data